FUNGAL DIASTASE 33.33MG WITH PEPSIN 5MG DROPS are a liquid pharmaceutical formulation incorporating Fungal Diastase and Pepsin as enzyme-based active components. Formulating an enzyme-based oral liquid requires appropriate consideration of ingredient stability, pH, temperature, viscosity, microbial quality and uniform distribution within the formulation. Since enzymes are biologically active substances, formulation and manufacturing conditions are appropriately controlled to ensure that the required product characteristics are maintained. For a pharmaceutical company developing a PCD Pharma Franchise portfolio, enzyme-based oral drops can be part of a diversified liquid formulation range, which has standardized quality specifications and suitable packaging.
The specified formulation consists of Fungal Diastase 33.33 mg with Pepsin 5 mg in the finished drop preparation. Both components are enzyme-based materials and require suitable formulation conditions to maintain their defined quality characteristics.
The liquid vehicle may contain pharmaceutical-grade water with suitable excipients such as stabilizing agents, sweeteners, flavors, preservatives, viscosity modifiers or other formulation aids, depending on the finalized product design.
Selection of the vehicle is an important element of formulation development because pH, ionic environment and excipient compatibility can influence enzyme stability. Pre formulation studies can therefore evaluate the impact of Fungal Diastase and Pepsin under different formulation conditions.
Parameters such as pH, viscosity, density, solubility or dispersion characteristics and compatibility with the proposed packaging system can be evaluated during development. The objective is to establish a homogeneous liquid formulation with consistent physical and chemical characteristics.
Uniform distribution of the enzyme components is an important consideration during manufacturing. The manufacturing sequence is designed according to the physical and stability characteristics of Fungal Diastase and Pepsin.
Raw materials are first subjected to appropriate identification and quality checks. The liquid vehicle and compatible excipients may be prepared separately under controlled conditions before incorporation of the enzyme components.
Depending on the finalized formulation, the enzymes may be introduced gradually under controlled agitation. Excessive mechanical mixing or unsuitable processing conditions may be avoided where they could adversely affect enzyme characteristics.
Temperature control can be particularly important during processing. The manufacturing process may therefore be designed to maintain appropriate temperature conditions during preparation and filling.
The order of addition, mixing speed and mixing duration are established during product development to achieve uniform distribution without unnecessary processing stress.
Bulk samples may be evaluated at different stages to confirm homogeneity before the product proceeds to filling.
Manufacturing of FUNGAL DIASTASE 33.33MG WITH PEPSIN 5MG DROPS begins with verification of raw materials and preparation of the selected liquid vehicle.
Where required, individual excipients may be dissolved or dispersed separately before being transferred into the main manufacturing vessel. The bulk vehicle is maintained under controlled agitation while the formulation components are incorporated according to the validated manufacturing sequence.
The enzyme components can be added under controlled conditions appropriate to the finalized formulation. Mixing should be sufficient to achieve uniformity while avoiding unnecessary aeration or excessive processing.
In-process parameters may include appearance, pH, viscosity, temperature, density and bulk homogeneity. These checks aid in confirming that the formulation is within established process limits.
After completion of bulk preparation, the liquid may be transferred to a suitable filling system. Accurate fill-volume control is important for maintaining consistency between individual containers.
The dropper assembly is also an important part of the manufacturing process. Filling and closure operations should be controlled to maintain appropriate container integrity and consistent dispensing performance.
Quality control of FUNGAL DIASTASE 33.33MG WITH PEPSIN 5MG DROPS consists of evaluation of the finished liquid formulation and its enzyme components. Appropriate analytical procedures should be established according to the finalized product specification.
The product may be tested for appearance, color, odor, pH, viscosity, density and fill volume. Homogeneity testing helps assess whether the formulation remains consistently distributed throughout the bulk.
For enzyme-containing products, activity-based or other suitable analytical procedures may be used to evaluate Fungal Diastase and Pepsin according to the applicable specification. The selected methods should be appropriately validated for their intended purpose.
Microbial quality is another important consideration for aqueous oral formulations. Appropriate microbiological testing can be incorporated into the quality-control program, alongside preservative-related evaluation, where relevant to the formulation.
The dropper system may also undergo performance testing to assess delivery consistency. Container-closure compatibility can be evaluated to identify potential interaction between the formulation and packaging materials.
Stability evaluation is particularly important for enzyme-containing liquid formulations. Studies can be conducted under defined conditions to monitor changes in physical appearance, pH, viscosity, enzyme-related characteristics, microbial quality and other applicable specifications.
Temperature and environmental exposure can influence the stability of enzyme-based ingredients, so stability programs should be designed according to the finalized formulation and packaging configuration.
Pharmaceutical-grade bottles with suitable dropper assemblies may be selected for packaging. The container-closure system should provide appropriate protection from environmental exposure while supporting consistent dispensing.
Compatibility studies can assess whether the bottle, dropper and closure materials interact with the formulation or influence its physical and chemical properties during storage.
Stability testing in the final packaging configuration can provide supporting data for establishing appropriate storage conditions and the proposed shelf life.
The packaging should also maintain adequate closure integrity during transportation and repeated handling.
FUNGAL DIASTASE 33.33MG WITH PEPSIN 5MG DROPS can be incorporated into a pharmaceutical company's liquid dosage-form portfolio, alongside syrups, suspensions, drops and other enzyme-based formulations. Standardized product specifications and consistent packaging can help maintain a professional and organized product catalogue.
For a PCD Pharma Franchise portfolio, the product can be presented with accurate composition, strength, packing size, manufacturer details, storage information and other approved product particulars. Packaging artwork should accurately represent the finalized formulation and comply with applicable regulatory requirements.
The development process involves raw-material qualification, vehicle selection, enzyme compatibility assessment, controlled incorporation, bulk mixing, filling, dropper evaluation, analytical testing and stability monitoring.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech